Biomarker Utilization in the Evaluation of Infection
To begin, there will be a thorough review of the biomarkers IL-6, CRP, and Procalcitonin. Additionally, literature will be evaluated for utilization of these biomarkers in diagnosis and discontinuation of antibiotics in bacterial infections, as well as assessment of literature for these biomarkers in severity and bacterial co-infections in COVID-19.
Target Audience
- Pharmacists
- Pharmacy Technicians
Learning Objectives
- Compare biomarkers with a focus on kinetics and relationship to bacterial versus viral infections
- Assess clinical utility of biomarkers in bacterial infections
- Evaluate literature for use of biomarkers in COVID-19 infection
- Describe differences between biomarkers with a focus on relationship to bacterial versus viral infections
- Recognize clinical utility of biomarkers in bacterial infections
- Review literature for use of biomarkers in COVID-19 infection
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System(1).docx | 79.15 KB |
Faculty
Sarah Harrison, PharmD, BCCCP
Planners
Brook DesRivieres, PharmD, MS, FACHE
Disclosure
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
FDA Off-Label Use
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
Disclosure Statements
Absence of Relevant Financial Relationships
None of the planners, faculty, or others in a position to control content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Pharmacists/ Pharmacy Technicians
Vizient, Inc. designates this activity for a maximum of for 1.00 contact hour(s) (0.1 CEUs) for all pharmacists and pharmacy technicians.
Universal Activity Number: UAN JA0006103-0000-22-066-L01-P
Universal Activity Number: UAN JA0006103-0000-22-066-L01-T
Reporting
Upon closing of the online evaluation, Vizient will report your CE credits directly to CPE monitor within 60 days.
Please note:
- After the course close date, Vizient will no longer be able to report credit(s) to CPE monitor.
- It is the responsibility of the pharmacist or pharmacy technician to ensure that your Vizient CE Learner Profile has the correct NABP e-profile ID and DOB (in MMDD format) to receive credit for participating in the activity.
- To track the status of the submission of your credits to NABP: please check the Reported Credit Tab in your Vizient CE account.
- To verify your credits were successfully submitted to NABP before the deadline: please check your NABP e-Profile account.
- For all other questions regarding your NABP e-Profile or CPE Monitor, please contact NABP directly.
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician